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The regulation of gene expression is central to cell biology. While gene 
expression is modulated at many levels, the interaction between DNA and site-
specific DNA binding transcription factors is a critical step. In metazoans, 
transcription factors usually exist in highly related families that exhibit a 
conserved preference for a particular DNA binding site. The ETS family provides 
a model for understanding how transcription factor families achieve distinct 
functions despite high conservation. With a focus on ETS1, genomic studies 
have identified two modes of ETS factor binding: redundant binding with other 
ETS factors, and specific binding of ETS1 only.  
The work presented in this dissertation uses genomic data from massively 
parallel sequencing experiments to refine the model of ETS factor occupancy in 
vivo. ETS-redundant and ETS1-specific binding events were found to be 
correlated with distinct recruitment motifs. ETS-redundant binding is co-incident 
with histone marks associated with active promoters while ETS1-specific binding 
is co-incident with histone marks associated with distal transcriptional enhancers. 
ETS1 co-localizes with the transcriptional co-activator CBP at enhancers, but not 
at promoters, suggesting different mechanisms of ETS1 function at these two 
recruitment sequences.   
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 Genome-wide disruption of ETS1 binding results in distinct expression 
profiles for genes near ETS-redundant and ETS1-specific binding events, 
confirming functional differences. At redundant promoters, disruption of ETS1 
occupancy also provided the first example of dynamic time sharing by ETS1 and 
GABPA, establishing the molecular basis of redundancy within the ETS family. 
Unexpectedly, genes near ETS1-specific binding events were upregulated upon 
ETS1 disruption, suggesting a previously unidentified mode of regulation at these 
targets. These results serve as a framework for future studies investigating the 
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Transcriptional regulation and transcription factors 
A key step in gene expression is the interaction between a DNA binding 
transcription factor and a specific recognition sequence. This genome-encoded 
recognition process facilitates the recruitment and assembly of basal 
transcriptional machinery, which includes RNA polymerase and a variety of co-
factors, including co-activators, co-repressors, and chromatin remodeling 
complexes, which ultimately regulate the transcription of RNA from the genomic 
template. Within the context of a cell, gene transcription must be highly regulated 
to respond to differing needs throughout the cell cycle. Within the context of an 
organism, additional layers of control must exist to establish and maintain a wide 
range of cell types. Gene expression is modulated at many points in this 
biological regulation, but transcription factor binding is a crucial and often 
misregulated step, making an understanding of transcription factor function 
central to many aspects of cell biology and pathogenesis.  
This thesis focuses on the transcriptional regulation of mRNA by RNA 
polymerase II (RNAPII) in the context of human cells (Figure 1.1).  Using the ETS 
family of transcription factors as a model, this work considers the ways in which 
divergent DNA binding sites, uniquely interacting protein-partners, and post-
translational modifications guide specific genomic occupancy and regulatory 




The ETS family of transcription factors 
As higher organisms have evolved, many, if not all, DNA binding 
transcription factors have undergone gene duplication events. As a result, the 
genomes of many organisms contain multiple members of a transcription factor 
family that are characterized by various degrees of conservation. Functional 
domains, such as DNA binding domains, are subject to selective conservation 
during evolution, thus many transcription factor families exhibit a conserved 
preference for DNA binding sequences [1]. In spite of having a shared binding 
site preference, there is evidence that within many transcription factor families 
individual members mediate distinct functions [2,3,4,5,6]. The work presented in 
this thesis explores the ways in which family members with highly conserved 
DNA binding domains identify and bind to distinct DNA motifs in the genome to 
perform unique biological functions.  
 One such family of regulatory proteins is the ETS family of transcription 
factors (Figure 1.2). The ETS family is characterized by a highly conserved DNA 
binding domain and is found in all metazoans; there are 8 ets genes in 
Drosophila melanogaster [7], 10 in Caenorhabditis elegans [8], and 28 in Homo 
sapiens [6]. Genetic studies in mouse models show distinct defects in mice with 
an individual ETS factor knocked out. Mouse phenotypes range from male 
infertility upon ETV4/5 knockout [9,10] to T cell and NK cell defects upon ETS1 
knockout [11,12]. Many of these mouse genetic experiments have been 
recapitulated in flies and worms, and suggest that individual members of the ETS  
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Figure 1.2 The ETS family of transcription factors The ETS family of DNA 
binding transcription factors contains a highly conserved DNA binding domain 
(the ETS domain, red), which binds to a core 5ʼ-GGAA/T-3ʼ DNA motif. Nearly 
1/3 of ETS factors (11/28) also contain a conserved structural domain termed 
the Pointed Domain (the PNT domain, green), which mediates protein-protein 
interactions. Several ETS factors are phosphorylated in response to signaling, 
as denote by a circled P. (Figure adapted from Hollenhorst et al. [6]) 
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family mediate distinct biological activity and regulate at least some unique 
genomic targets. 
 
The ETS family specificity conundrum 
Genetic experiments suggest discreet functions for ETS factors, yet 
multiple ETS family members are expressed within a single cell type [13,14].  
This seeming incongruity frames a central conundrum in transcriptional 
regulation. How do closely related factors, co-expressed within a single cell, 
select unique transcriptional targets and maintain specificity of function? 
The simplest explanation for specificity of function is that ETS family 
members have preferences for distinct DNA motifs. Over the past two decades 
many groups have performed site selection experiments to determine the 
preferred DNA binding sites of ETS family members [15,16,17,18,19,20,21,22]. 
Through systematic evolution of ligands by exponential enrichment (SELEX) and 
other multiplex binding assays, these studies have identified a highly conserved 
ETS binding site, 5ʼ-GGAA/T-3, with variable but largely conserved flanking base 
that provide cooperative increases in DNA binding affinity [22]. While subtle 
differences have been identified between family member binding sites, it is more 
notable how strikingly similar the sequence preferences are across the family.  
A recent study using protein binding microarrays to identify the DNA 
binding site preferences of 27 human ETS factors identified subtle but distinct 
site preferences within the four clades of the ETS family [23] (Figure 1.2). For 
example, ETS factors in Clade III prefer a 5ʼ-GGAA-3ʼ binding site while those in 
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Clade IV prefer a 5ʼ-GGAT-3ʼ. However, the differences in preferred binding sites 
were subtle and within a given clade there are often diverse functions. For 
example, Clade I contains the PEA3, TCF, ETS, ERF, and ERG subfamilies, 
representing over half of all known ETS factors and a diverse set of biological 
functions.  
It is clear that DNA binding sites play a role in determining specific ETS 
factor function, but in vitro identification of high-affinity sites is not sufficient to 
characterize this mechanism. The above studies do not address binding 
preference for low- and medium-affinity binding sites, and frame the possibility 
that unique target selection by ETS factors may be mediated by sequences that 
diverge from the strongest, consensus sites. To address this possibility, ETS 
factors must be considered in the biological context of their structural domains, 
protein partners, and post-translational modifications, and ultimately occupancy 
should be determined in vivo.  
 
Structured domains within the ETS Family 
Many structured domains have been identified in the ETS family, but three 
structural domains are most common in the family: the ETS domain, the DNA 
binding domain that defines the family; the PNT domain, an interaction domain 
possessed by ~1/3 of the family; and autoinhibitory domains, which while not 




The ETS domain  
All ETS factors contain a conserved DNA binding domain, the ETS 
domain, consisting of ~85 amino acids that fold into a winged-helix-turn-helix 
structure [6,24]. The ETS domain selectively binds to DNA motifs based on 
discrimination of 9 base pairs, and 5ʼ-ACCGGAAGT-3ʼ is the most commonly 
preferred site [23]. 
This domain is largely invariant, though there are examples of protein 
partners interacting specifically with the ETS domain of a particular factor, such 
as the interaction of PAX5 with ETS1 on the mb-1 promoter [25,26]. Within an 
ETS factor, cis-interactions can also influence ETS domain binding to DNA. The 
ETS factors ELK1 and ELK4 contain identical DNA binding domains, but non-
conserved residues distal to the ETS domain distinct conformations of the factors 
upon association with the consensus DNA binding site [27,28]. While this study 
considered ELK1 and ELK4 binding on the same site, it does highlight the 
possibility that cis-interactions with the ETS domain could mediate distinct 
binding preferences.  
 
The PNT domain  
In addition to the characteristic DNA binding domain, 11 of the 28 human 
ETS proteins contain a domain called the Pointed domain, or the PNT domain, 
named after the ETS1 Drosophila ortholog, Pointed-P2 [29]. The PNT domain 
term is used exclusively for ETS factors, the fold [30,31,32] is structurally similar 
to that found in the sterile !-motif domain, or SAM domain [33,34,35]. SAM 
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domains have been shown to interact with SAM and non-SAM protein domains, 
as well as with RNA and other molecules [36], linking the ETS family 
evolutionarily to proteins of diverse function.  
The PNT domains of multiple ETS factors interact with the homologous 
lysine acetyl-transferases (KATs) CBP/p300 [37,38,39] [40] [41]. The interaction 
between ETS-PNT and CBP/p300 is essential for the transcriptional function of 
many ETS factors, presumably because histone acetylation establishes a 
transcriptionally permissive environment and mediates the recruitment of the 
basal transcriptional machinery. It was observed that ETS1-driven transcription is 
enhanced by RAS- mitogen-activated protein kinase (RAS-MAPK) signaling [42], 
and later shown that ETS1-PNT serves as a kinase docking site for ERK1/2 [43]. 
Upon docking at ETS1-PNT, ERK1/2 can phosphorylate ETS1 at two residues N-
terminal to the PNT-domain [44,45]. This phosphorylation enhances the 
interaction of ETS1-PNT with the homologous lysine acetyl-transferases (KATs) 
CBP/p300 [46], increasing the transactivation function of ETS1, further building 
on the significance of the ETS-PNT.  
Other co-factors have been implicated in interactions with ETS1-PNT, 
such as the ubiquitin ligase UBC9 [47] and the histone deacetylase Daxx [48]. 
Additionally, the PNT of the ETS factor ETV6 is capable of homotypic 
polymerization [49], facilitating cooperative DNA binding and perhaps by 




Autoinhibitory domains in ETS factors  
The term autoinhibition (AI) refers to the attenuation of DNA binding by a 
cis-element, and while AI domains are not necessarily conserved structures, they 
are widely used across the ETS family. ETS factors that regulate through AI 
include ETV4 [51,52], ETV5 [53], ETV6 [50], and members of TCF sub-family 
[54].  
The best characterized case of AI in the ETS family, however, is ETS1 
[55], and the AI domain is a dynamic point of regulation for the ETS1 protein. The 
AI domain of ETS1 is signaling responsive [56,57,58,59], is alternatively spliced 
in different isoforms of ETS1 [60,61,62], and is thought to interact with the 
transcription factor RUNX1 [63]. Taken together, the diversity of functional 
mechanisms derived from the ETS1 AI domain illustrate the number of 
permutations available to fine tune transcriptional function and drive DNA binding 
site specificity.  
 
Protein partners of ETS1 
The ETS family has been implicated in numerous protein partnerships, 
which can serve to target particular ETS factors to unique genomic targets. Some 
partnerships are shared among family members, such as the interaction of PU.1, 
ERG, ELF1, and other ETS factors with the transcription factor JUN [64,65,66]. 
Other partnerships are unique to a particular factor, such as the interaction of 
GABPA with its non-DNA binding subunit GABPB [67]. While many factors have 
been shown to interact with ETS1, here we focus here on two partners that have 
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been shown to be relevant in the context of DNA motif specificity: RUNX1 and 
PAX5.  
 
ETS1 forms a protein partnership with RUNX1  
RUNX1 is a member of the Runt-family of transcription factors, and is 
important for hematopoietic development and B cell function. In vitro DNA binding 
and biochemical studies have shown that ETS1 and RUNX1 cooperatively bind 
to a motif found in the MoMLV enhancer [63]. This enhancer contains the motif 
5ʼ-CAGGATATCTGTGGTAAGC -3ʼ, which is comprised of a weak ETS motif 
(GGAT) and a degenerate RUNX motif (TGTGG). While the individual sites are 
unfavorable, in vitro and in vivo occupancy has been observed for ETS1 and 
RUNX1 at this motif. Truncation experiments show that cooperativity at this site 
requires the ETS1 AI domain, suggesting that RUNX1 relieves ETS1-
autoinhibition, though a direct physical interaction between RUNX1 and the ETS1 
AI domain has not been defined [63]. In addition to facilitating cooperative DNA 
binding by unphosphorylated ETS1, it has been reported that RUNX1 interacts 
with the phosphatase calcineurin, which de-phosphorylates ETS1-SRR [68], 
though it should be noted that these experiments involved overexpression of 
calcineurin at nonphysiological levels.  
 
ETS1 forms a protein partnership with PAX5  
Like RUNX1, PAX5 is a transcription factor important for B cell function. 
Through a cooperative interaction with the ETS domain [25], ETS1 and PAX5 
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bind to a highly unfavorable composite motif in the mb-1 promoter to drive gene 
expression [25,26,69]. This interaction is mediated by four residues in the ETS1-
ETS domain, and ETS factors containing three out of four of these conserved 
residues, including ELK1 and ELK3, were also shown to interact with PAX5 [69]. 
These interactions were less efficient, however, and the investigators postulate 
that the strength of the ETS1-PAX5 interaction encourages ETS1 specificity at 
the composite site in vivo. These two examples build the case that combinatorial 
control could provide a route to specificity, as partner proteins can facilitate ETS 
factor binding at composite sites that diverge from the consensus. 
 
ETS1 responds to several signaling pathways 
Cellular signaling regulates transcription factor function. By modulating 
nuclear localization, DNA binding affinity, and/or interactions with other 
transcriptional regulatory proteins, transcription factors can respond to diverse 
signals with a high degree of fine tuning [70]. Here we focus on RAS-MAPK and 
calcium signaling, both of which impinge on the ETS1 protein (Figure 1.3). 
 
ETS1 responds to RAS-MAPK signaling 
The RAS-MAPK pathway is a signaling cascade that impinges on multiple 
ETS family members to affect transcriptional function. Upon growth-factor 
stimulation of membrane bound receptors, the RAS GTPase transmits the 
extracellular signal from receptor tyrosine kinases (RTKs) through a kinase 
cascade to MAPKs. Activated nuclear MAPKs can phosphorylate target  
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transcription factor substrates, connecting the initial extracellular stimuli to a 
transcriptional readout.  
Upon RAS-signaling, the MAPK ERK1/2 phosphorylates ETS1 and ETS2 
in an unstructured region N-terminal to the PNT-domain. This phosphorylation 
event induces a conformational change in the PNT domain and enhances the 
interaction affinity between PNT and CBP/p300, thus affecting ETS1 driven 
transcription [42,44,45,46]. Similarly, MAPK phosphorylation of the ETS family 
member ELK1 enhances transcription through an interaction with CBP/p300 
[71,72]. Upon ELK1 phosphorylation, the conformation of this interaction 
changes, increasing the DNA binding affinity of ELK1 and facilitating enhanced 
KAT activity of CBP/p300 [73]. These two examples of RAS signaling to ETS 
factors feature many of the same players, but utilize different mechanisms to 
respond to signaling, underscoring the use of signaling to functionally distinguish 
similar factors.   
 
ETS1 responds to calcium signaling 
Extracellular signals are transmitted to the nucleus is through regulation of 
internal stores of calcium as a signaling molecule. Upon receptor engagement, 
the enzyme phospholipaseC (PLC) is activated and catalyzes generation of the 
second messenger molecules diacylglycerol (DAG) and inositol trisphosphate 
(IP3). IP3 then binds to an endoplasmic reticulum (ER) bound IP3–receptor and 
stimulates the opening of ER Ca2+ channels, resulting in a large flux of 
cytoplasmic calcium ions. The increase in cytoplasmic calcium activates the 
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calcium/calmodulin-dependent protein kinases II (CaMKII). Activated CaMKII can 
phosphorylate ETS1 at multiple residues in the SRR flanking the C-terminal ETS 
domain [56,58]. This phosphorylation stabilizes the AI domain, resulting in an up 
to 50-fold inhibition of DNA binding affinity [57,58,59]. The extent to which DNA 
binding affinity is decreased is directly correlated with the number of phosphates 
modifying the SRR, serving as a rheostat to fine tune ETS1 binding affinity [58]. 
Using artificial reporter constructs, calcium signaling has been shown to reduce 
the expression of the ETS1 target GS-CSF [74], but the comprehensive biological 
relevance of this signaling was not well understood.  
 
Combining specificity mechanisms diversifies functionality 
The above discussion considered mechanisms of achieving specificity as 
discrete functions, but in many cases these mechanisms are used in combination 
to further regulate transcriptional function. This provides the ETS family, and 
transcription factors in general, with a large arsenal of tools to achieve specificity. 
For example, ETS1 is regulated by autoinhibition; calcium signaling reinforces 
autoinhibition; and a protein partnership with RUNX1 relieves autoinhibition. Each 
of these three mechanisms represents a layer of specificity that can individually 
regulate ETS1 function, or can combinatorially fine tune ETS1 specificity.  
 
In vivo occupancy of transcription factors 
Thus far, we have considered in vitro biochemical studies to examine 
functionality of the ETS family. In order to understand this functionality in a 
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biological context, however, we must understand the genomic occupancy of ETS 
factors in vivo. Within a cell, what are the genes that a particular ETS factor 
regulates, and is this regulation exclusive for that ETS factor or redundant across 
the family? 
 Until recently, transcriptional regulatory elements were determined by 
using artificial reporter constructs in in vitro assays. By positioning a putative 
regulatory region upstream of a reporter gene and making mutations or 
truncations, the cis-elements driving transcription and in many cases the 
associated DNA binding protein, could be identified. While these techniques 
illuminated many of the basic principles of transcriptional regulation, they are time 
consuming and labor intensive. Identification of regulatory elements was limited 
to a small subset of genes, and consideration was limited to 1-2 kilobases (kb) 
flanking the transcription start site (TSS). Further, these studies relied on 
exogenous reporter constructs that do not necessarily recapitulate endogenous 
loci in terms of chromatin state, genomic position, and interactions with distal 
regulatory regions.   
While a handful of ETS-target genes were identified using basic genetic 
approaches, the vast majority of ETS factor targets remained unknown until the 
development of the chromatin immunoprecipitation (ChIP) technique, which maps 
the in vivo association of endogenous factors with DNA [75]. The technique 
involves chemically crosslinking live cells to stabilize chromatin, shearing 
crosslinked chromatin to 300-1000 base pair fragments immunoprecipitating with 
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an antibody against the factor of interest, and reversing crosslinks to isolate the 
associated DNA for PCR or other analysis. By combining ChIP with microarray 
technology (ChIP-on-chip) [76] or more recently with massively parallel 
sequencing techniques (ChIPSeq) [77], transcription factor occupancy can be 
identified in vivo on a large scale. An important distinction between ChIP-on-chip 
and ChIPSeq is that due to the size of the human genome, the former requires 
tiling of a discrete set of known genomic elements on a microarray, usually 
regions -5kb to +2kb around a TSS, while the latter has the advantage of de novo 
sequencing and can thereby identify previously unknown regulatory elements.  
 
Genomic targets of the ETS Family 
To determine the transcriptional targets of ETS1 and other ETS factors, 
ChIP-on-chip using promoter microarrays was performed for the ETS factors 
ETS1, GABPA, ELF1, and ELK1 [78,79]. Because ETS1 is predicted to have a T 
cell specific function [11,12], experiments were carried out in a human T cell line. 
Unexpectedly, a large subset of the identified ETS targets were not unique to a 
particular factor, and at many promoter regions redundant occupancy of all 
examined ETS factors was observed. Motif analysis revealed that redundantly 
occupied promoters contain a high-affinity consensus site, 5ʼ-CCGGAA-3ʼ, and 
are frequently associated with the promoters of housekeeping genes.  An ETS1 
specific class was also identified in this study, and many of these regions were 
found to contain a lower affinity ETS site, often juxtaposed with a weak RUNX 
binding site [78]. These findings have been incorporated into the working model 
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of ETS factor function: high-affinity sites in the promoters of housekeeping (HK) 
genes mediate redundant ETS factor function and low-affinity composite sites 
mediate specific ETS factor functionality (Figure 1.4). 
 While this study revealed a great deal about the genomic occupancy of 
ETS factors, it opened up several broad questions. First, while a subset of ETS1 
specific targets were identified, the neighboring genes were unrelated to the 
observed phenotype of the ETS1 knockout mouse, and it was unclear how – or if 
– ETS1 directly regulates the expression of T cell genes.  
In addition to this question of specific ETS1 function, the surprising 
prevalence of redundant ETS factor occupancy raised a number of questions 
regarding the nature of redundancy. For example, do ETS factors time share an 
individual binding site in a single cell, or does redundancy reflect the average 
occupancy of that loci across all cells assayed? Further, is the function of ETS 
factors at redundant sites truly redundant, meaning that one ETS factor can fully 
compensate for the function of another ETS factor at these sites?  
Reporter constructs have shown transcriptional functionality of redundant ETS 
binding events [80], but these assays lack endogenous context. Correlating 
endogenous gene expression with in vivo factor occupancy provides a 
biologically relevant way to confirm the functionality of DNA binding events. For 
example, gene expression studies have been used to identify previously 
unknown functional mechanisms for estrogen receptor (ER) mediated down 
regulation [81,82] and have led to the validation of numerous p53  
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transcriptional targets that in vitro assays could not have identified [83]. However, 
because of inherent inconsistencies in probe quality, microarray experiments 
require comparison to a reference state, making it difficult to quantify the 
expression of genes which are expressed across nearly all cell types and in most 
cellular conditions. Thus, the in vivo functionality of redundant ETS binding 
events is unclear.  
 
Transcription factors may bind several distinct sites   
Different transcription factor families have different requirements for 
recruitment motifs. The occupied loci of some factors, such as the STAT [77] and 
ETS families [78], are enriched for sequences similar to known binding sites 
previously identified in vitro. Other factors, such as the E2F family, show almost 
no proclivity for the high affinity sequences derived in vitro or any other site [84], 
leaving open the question of how E2F factors select their targets in vivo.   
Of factors that do preferentially bind a known consensus sequence, there 
is no doubt diversity in the sites occupied. An experiment performed using 
protein-binding microarrays and 104 mouse transcription factors found that half of 
the queried factors bound two or more distinctly different sites with high-affinity 
[85]. Crystallographic experiments have shown that the hormone responsive 
transcription factor glucocordicoid receptor (GR) adopts different structural 
conformations based on binding site differences as subtle as a single nucleotide 
[86], and that these conformational differences impact GR transcriptional 
function. This example highlights that dual- or multi- site recognition by a 
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transcription factor could provide an additional control for functional regulation of 
transcription, and in vivo determination of factor occupancy is likely to reveal a 
large complement of sites used by transcription factors.  
 
Genome organization 
Another insight revealed by genomic experiments and bioinformatics is 
that very few of the possible genomic binding sites for a particular factor are 
occupied in vivo [76,87,88,89]. While the inherent affinity of a transcription factor 
for a binding site certainly plays a role in determining occupancy, genome 
organization is equally important. Genetic material is highly packaged, with 
genomic DNA wrapped around histone octamers, or nucleosomes, to form 
chromatin [90,91]. The structure of this packaging can be modulated to make 
particular regions of the genome more or less accessible and dictates where, and 
with what affinity, transcription factors bind DNA. To a large extent, differences in 
the accessibility of the genome are what lead to the diversity of gene expression 
profiles across different cell types [92]. There are a number of factors that can 
influence the relative accessibility of DNA, including histone marks and DNA 
methylation. The interplay of these factors can establish a wide range of 
chromatin environments, guiding transcription factor occupancy and ultimately 





Gene regulatory elements 
It has long been known that the chromatin packaging of gene promoters, 
or regions proximal to the TSS of RNAPII transcribed genes, is generally open 
and is therefore accessible to transcription factors. Because these regions are 
accessible, they are susceptible to DNase cleavage assays, and DNaseI-
hypersensitivity (DNaseHS) is often used as a readout to identify novel genes 
and regulatory elements [93,94]. Though proximal promoters are the most well 
studied type of regulatory element, genome-wide DNaseHS studies have 
highlighted the abundance of other types of functional elements [95]. 
Transcriptional enhancers, distal elements that promote transcription, are also 
regions of open chromatin and are more prevalent in the genome than 
promoters. DNaseHS assays in multiple cell types reveal that while promoter 
regions are near- universally open, the accessibility of enhancer regions varies 
by cell type [96], suggesting that distal enhancers, not promoters, define cell type 
specific expression programs. As discussed above, ETS factor occupancy had 
been determined at transcriptional promoters as well as at enhancers, but it was 
not clear if ETS factors play the same role in these two different contexts.  
 
Histone marks 
Histone tails can accept many different covalent modifications, including 
acetylation, methylation, phosphorylation, ubiquitylation, and sumoylation. 
Promoter and enhancer elements are correlated with a specific signature of 
histone marks that regulate local accessibility. Histone marks can regulate 
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chromatin environment directly by disrupting DNA-nucleosome contacts or 
indirectly by recruiting chromatin modifying factors.  
Histone acetylation is invariably associated with transcriptional activation, 
facilitated through the ʻpuffingʼ or de-condensing of acetyl-rich chromatin. Histone 
acetyltransferases (HATs) are grouped into three main families, GNAT, MYST, 
and CBP/p300, and are generally promiscuous in their targets (reviewed in [97]). 
The transcriptional effects of histone methylation are more diverse, with H3K4-, 
H3K36-, and H3K79-methylation being implicated in transcriptional activation and 
H3K9-, H3K27-, and H4K20-methylation being implicated in transcriptional 
repression (reviewed in [98]). Histone methyltransferases (HMTs) are typically 
substrate specific, and it is not unusual for a single HMT to deposit a single 
specific methyl mark.  
Relative to the rest of the genome, promoters are depleted of 
nucleosomes, with a marked nucleosome free region at the TSS. The 
nucleosomes nearby are hypoacetylated and marked with H3K4me3 [99,100], a 
hallmark of active transcription. This mark is added by the HMT SET1 [101], 
which physically associates with active RNAPII [102]. Enhancers, on the other 
hand, are not marked with H3K4me3, but with H3K4me1 [103], highlighting the 
diversity and specificity of methyl-marks. Enhancers are also enriched for 
H3K9ac or H3K14ac [104], perhaps because of high CBP/p300 HAT occupancy, 
but these marks are not specific to enhancers and generally mark regions of 
active chromatin. The relationship, if any, between ETS factors and histone 
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marks had not been determined, and we postulated that correlation with unique 




Like histones, DNA can be covalently modified as a mechanism of 
regulating transcription. DNA methyl transferases, DNMTs, can facilitate the 
addition of a methyl-group to the cytosine of 5ʼ-CpG-3ʼ dinucleotides, and this 
modification can repress transcription by recruiting additional repressive proteins 
or by disrupting transcription factor binding sites. This method of regulation is of 
particular interest in the context of the ETS family, because the ETS consensus 
site, 5ʼ-CCGGAA-3ʼ, contains a CpG dinucleotide. Several ETS family members 
have been shown to be sensitive to site methylation [105,106](S.C. unpublished 
data). Based on this sensitivity DNA methylation could be a key factor in 
determining ETS factor occupancy at consensus sites. As mentioned above, the 
5ʼ-CCGGAA-3ʼ ETS consensus site most frequently occurs in TSS proximal 
promoters, which are largely hypomethylated regions (reviewed in [107]). Though 
the causal relationship between ETS factor occupancy and hypomethylation has 
not been explored, the correlation is striking, and sets the stage for future 
examining the potential function of ETS factors at housekeeping promoters. One 
possibility is that ETS factors bind with high-affinity to CpG-containing sites to 
protect the site from methylation and thereby ensure constitutive expression, a 
mechanism which has been described for the transcription factor MLL, which 
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occupies a CpG-containing binding site in the Hoxa9 promoter to protect the site 
from methylation [108]. Because all ETS factors have the ability to bind high-
affinity CpG-containing sites, we postulate that CpG protection could be the 
redundant function of ETS factors.  
 
The focus of this thesis 
The ETS family provides a model for understanding how transcription 
factor families achieve distinct functions despite high conservation. At the 
commencement of this work,  analysis of ETS factor binding to promoter regions 
had identified two modes of ETS1 binding: redundant binding with other ETS 
factors, and specific binding of ETS1 only. The work presented in this dissertation 
uses data sets generated by massively parallel DNA sequencing techniques to 
refine the model of ETS factor occupancy in vivo, and highlights the structural, 
biological, and behavioral differences between different types of ETS1 occupied 
regulatory elements.  
In Chapter 2, we established that ETS-redundant and ETS1-specific 
regulatory elements are associated with distinct chromatin landscapes, DNA 
recruitment motifs, and ontological gene sets. Using a genome wide approach, 
we identified a large number of previously unidentified transcriptional enhancers, 
which were found to be mediated by a degenerate ETS binding motif and often 
occur near T cell-specific genes. Overlaying histone mark profiles on ETS-factor 
occupancy data, we found that ETS-redundant and ETS1-specific regulatory 
elements are correlated with marks of active promoters and transcriptional 
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enhancers, respectively. We also found a striking co-localization of ETS1 and the 
transcriptional co-activator CBP at enhancers, but not at promoters, suggesting 
that ETS1 may behave differently at these two recruitment sequences.   
In Chapter 3, we disrupted ETS1 binding genome wide to reveal distinct 
behaviors for ETS-redundant and ETS1-specific target genes and illustrating the 
separate biological functions of redundant and specific target genes. At 
redundant promoters, disruption of ETS1 occupancy has provided the first 
example of dynamic time sharing by ETS1 and GABPA, establishing the 
molecular basis of redundancy within the ETS family. Unexpectedly, expression 
analysis over a time course of ETS1 disruption revealed upregulation of genes 
near ETS1 specific binding events, suggesting a previously unidentified mode of 
regulation at these targets. These results have important implications for 
understanding how ETS1 functionally mediates different transcriptional programs, 
and suggests a model of ETS family function wherein specificity is a continuum 
rather than a dichotomy. 
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DISRUPTION OF ETS1 OCCUPANCY REVEALS 
 






Understanding how transcription factor families mediate distinct functions 
despite highly conserved DNA binding site preferences is a central question in 
gene regulation. With a focus on ETS1, we previously established a model of 
ETS factor function involving two distinct modes of recruitment: redundant ETS 
recruitment using a high-affinity consensus site, and specific ETS1 recruitment 
using a low-affinity degenerate site. Here, we disrupt ETS1 binding in vivo to 
determine the molecular basis of redundancy and refine our model of ETS factor 
function. At redundant sites, increased GABPA occupancy compensated for 
disruption of ETS1 occupancy and global expression analysis verified constitutive 
transcription of nearby genes. At ETS1 specific sites, GABPA did not 
compensate for disruption of ETS1 occupancy, and neighboring genes were 
unexpectedly upregulated. These findings build on the previous model of ETS 
family function in two ways: 1) they suggest that redundancy represents a time 
sharing mechanism where ETS factors take turns sampling an individual binding 
site, and 2) they highlight that specificity within the ETS family is likely a 
continuum rather than a strict dichotomy. We hypothesize that ETS2 may play a 
role in the upregulation of ETS1 specific target genes, and future studies will 
address the continuum of specificity for highly conserved family members like 





Metazoan genomes are characterized by groups of related genes that are 
derived from gene duplications during evolution. The diversification of function of 
these gene families enhanced the capacity of evolving metazoans to achieve 
new tissue types and other complexities. Yet, within these gene groups functional 
domains often retain highly conserved properties. Functional domains, such as 
DNA binding domains, are subject to selective conservation during evolution, and 
transcription factor families often exhibit a conserved preference for DNA binding 
sequences [1]. Transcription factor families vary widely in size, from the 
extremely large nuclear receptor group to the four-member Sp group, but nearly 
all families have been implicated in mediating a range of individual functions 
[2,3,4,5,6]. Thus, understanding how highly related transcription factors perform 
distinct functions is a central issue in the overall understanding gene regulation.  
The ETS family of transcription factors provides a model system to 
address this conundrum of specificity. There are 28 ets  genes in humans, all 
containing a highly conserved DNA binding domain, the ETS domain, which 
preferentially binds a core DNA sequence, 5ʼ-GGA(A/T)-3ʼ. The family is widely 
represented across metazoans; there are 8 ets genes in Drosophila 
melanogaster [7], 10 in Caenorhabditis elegans [8], and 28 in Homo sapiens [6]. 
Mouse knockout models show distinct defects in mice with individual ETS factor 
deletions, suggesting unique functions for different members of the ETS family. 
Mouse phenotypes highlight the diverse biology of the ETS family, and range 
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from male infertility upon ETV4/5 knockout [9,10] to hematopoietic cell defects 
upon ETS1 knockout [11,12]. This specificity is not driven by cell type restricted 
expression because a given cell type expresses multiple ETS factors, 
representing a diverse network of ETS factors in an individual cell [13,14]. Thus, 
it is clear that molecular and genomic mechanisms exist to determine specific 
functions within the context of the ETS network, and in vitro and in vivo studies 
have begun to shed light on these mechanisms. 
In vitro studies that select high-affinity binding sites have shown that 
binding site preferences across the ETS family are nearly identical 
[15,16,17,18,19,20]. More recently, high-throughput protein binding microarrays 
have been used to assess the DNA binding preferences of 27 human ETS 
factors [21]. The factors were classified into four distinct clades, and like previous 
experiments, this study found remarkable concordance of the sites recognized by 
the family. ETS factors in Clade I, a subgroup that contains over half of all ETS 
factors, showed no distinguishing preferences for the core DNA binding site. 
Slight differences in preference were observed in the three ETS factors in Clade 
III, PU.1, SPIB, and SPIC, which preferred a 5ʼ-GGAA-3ʼ binding site, and the 
sole ETS factors in Clade IV, SPDEF, which preferred a 5ʼ-GGAT-3ʼ binding site. 
These differences were subtle, however, and it is unlikely that preferences of the 
core DNA recognition sequence provide adequate specificity to drive the diverse 
biological functions of the ETS family. 
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While degenerate residues flanking the 5ʼ-GGA-3ʼ of the ETS binding site 
can make a site thermodynamically unfavorable, divergence from high-affinity 
sites could provide greater flexibility to discriminate between ETS factors. Indeed, 
in vitro studies on individual ETS factors indicate that specificity is mediated by 
low-affinity binding sites. For example, structural studies have shown that specific 
contacts between the PU.1 ETS domain and degenerate residues flanking the 
core ETS sequence drive PU.1 specificity at a low-affinity binding site [22,23]. 
Cell based reporter experiments suggest that a low-affinity binding site in the 
promoter of the IL2 gene, 5ʼ-ATATAGGAAGTG-3ʼ, mediates ELF1 specific 
occupancy and transcriptional regulation [16]. Mutation of this site to a high-
affinity ETS site decreases transcription, possibly through interference by other 
ETS factors like FLI1.  
In vivo experiments, including the determination of genome wide 
occupancy profiles for a handful of ETS factors, are beginning to reveal distinct 
biological roles for high- and low- affinity binding sites.  At high-affinity binding 
sites, a striking degree of ETS factor redundancy has been observed, despite the 
fact that diverse ETS factors have been considered [21,24,25,26]. Redundant 
occupancy of ETS factors is most frequently observed between 20 bp and 40 bp 
upstream of transcription start sites (TSS) of genes associated with ʻhouse-
keepingʼ (HK) functions [24,25]. Fine mapping of the occupancy of ETS1 and 
GABPA reveals strong co-localization of the factors, occurring at a motif closely 
matching the in vitro derived ETS consensus site [25].  
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In contrast to the redundant function of high-affinity sites, low-affinity sites 
are associated with the occupancy of a specific ETS factor and can involve 
heterotypic interactions such as the interaction between ETS1 and RUNX1 
[24,25] or between ELK1 and SRF [26]. Specific binding events frequently occur 
distal to the nearest TSS (>500 bp), and in the case of ETS1, neighboring genes 
are associated with cell type specific hematopoietic function. These results, as 
well as in vitro experiments, contribute to the working model of ETS family 
function: ETS factors redundantly regulate constitutive HK gene expression 
through high-affinity, promoter proximal binding sites, and individual ETS factors 
regulate cell-type specific expression through low-affinity, promoter distal binding 
sites. 
This model sets a frame work for ETS factor function, but several key 
features of the model remain unclear. While analysis of individual HK genes has 
suggested active transcription, genome-wide confirmation that redundant ETS 
targets are actively transcribed has not been established. The promoters of HK 
genes are correlated with identifiers of active promoters and constitutive 
expression, such as DNaseI hypersensitivity, H3K4me3, and high promoter PolII 
occupancy across diverse cell types [27,28,29,30], but comparative probe-based 
gene expression techniques (e.g., microarray) are not sufficient to quantitatively 
establish expression of genes that are constitutively expressed across all cell 
types. Thus, while the model of ETS factor function suggested that active 
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transcription is mediated from redundant binding sites, this hypothesis had not 
been confirmed.  
Additionally, while it is established that redundant ETS factor occupancy 
occurs at the same binding site [25], the molecular mechanism of how multiple 
ETS factors ʻshareʼ a site was unclear. We hypothesized that the observed 
redundancy is likely a result of one of two mechanisms: 1) different ETS factors 
occupy the site in different cells and the observed redundancy reflects average 
occupancy in a heterogeneous population; or 2) different ETS factors time share 
a single site in a dynamic equilibrium within a single cell. If the latter model is 
correct, disruption of one ETS factor would shift the equilibrium of ETS factor 
occupancy. Thus, these two models could be distinguished by disrupting an ETS 
factor in vivo and observing the behavior of other ETS factors. To date, however, 
traditional RNAi has not been successful in distinguishing this model because 
most ETS factors contribute to the expression of other ETS factors, resulting in 
off target effects. In this study, we postulate that phosphorylation dependant 
inhibition of ETS1 DNA binding, which has been studied extensively in vitro, may 
serve as a tool to overcome the limitations of RNAi and allow rapid, in vivo ETS 
network perturbation. Activated calcium/calmodulin dependant kinase II (CaMKII) 
phosphorylates ETS1 at multiple serines in a flexible, serine rich region (SRR) 
near the ETS domain [31], resulting in a 10-fold reduction of the DNA binding-
affinity of ETS1 [32,33,34]. While the phosphorylation of ETS1 in cells has been 
characterized in mouse cell lines [31] and in vivo calcium signaling is correlated 
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with reduced expression of an ETS1-driven reporter construct [35], the global 
impact of ETS1 phosphorylation in vivo was not understood.  
Here we seek to develop calcium signaling as a biological tool for 
perturbing the ETS network in vivo, both to validate the functional relevance of 
ETS1 phosphorylation in vivo and to distinguish between the two models of 
redundancy. Specifically, we consider how ETS1 disruption affects the 
equilibrium of ETS factor occupancy and the expression of previously identified 
ETS target genes. Upon disruption of ETS1 occupancy, we observed enhanced 
occupancy of GABPA at redundant sites but not at ETS1 specific sites. Using 
RNASeq, we determined that the expression of ETS-redundant target genes was 
unaffected by the shift in ETS factor equilibrium, suggesting that GABPA binding 
is compensatory and functionally redundant. At ETS1-specific target genes, 
disruption of ETS1 binding was unexpectedly correlated with transcriptional 
upregulation, and future studies will consider the basis of this increased 
transcription. This finding indicates that site preference in the ETS family is a 
continuum of specificity rather than a dichotomy of redundant and specific sites. 
 
Results 
Perturbing the ETS network in T cells 
The pharmacological stimulation of Jurkat T cells was used as a model to 
induce calcium-dependent phosphorylation of ETS1. To establish the model, we 
confirmed previous in vivo studies on calcium signaling [31,36] and established a 
time course of ETS1 phosphorylation in our system. Jurkat cells were activated 
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with phorbol-12-myristate-13-acetate (PMA) and ionomycin calcium ionophore, 
and harvested at the following time points: 2 min, 10 min, 30 min, 1 hr, and 3 hr. 
Western blot analysis was performed on whole cell lysates of the sampled 
populations (Figure 3.1). Long-exposure analysis of total ETS1 revealed two 
major ETS1 isoforms expressed in Jurkat cells (exposure not shown), previously 
identified and referred to as p42 and p51 based on electrophoretic mobility 
[37,38]. After 2 min of activation, we observed a mobility shift of p51, but not p42. 
The shorter ETS1 isoform lacks exon VII, which contains the SRR, indicating that 
the shift in p51 was likely due to ETS1-SRR phosphorylation. Western blot with a 
phosphospecific antibody for ETS1-S251P, one of the SRR phosphorylation 
events, verified that the shifted species is ETS1-SRR phosphorylated.  Note the 
complete absence of ETS1 calcium-dependent phosphomark in the resting state. 
After 30 min of activation, the p51 species was entirely shifted, indicating that all 
or nearly all of the ETS1 in the cell was SRR-phosphorylated. After 1 hr of 
activation, the phosphomark declines and was not detectable by 3 hr. Between 5 
hr and 8 hr postactivation, ETS1 levels declined, a phenomena previously 
reported by [39].  
 
ETS1-SRR phosphorylation reduces global  
ETS1 DNA binding in vivo  
To determine if ETS1-SRR phosphorylation reduces DNA binding in vivo, 
we performed ETS1 ChIPSeq on cells activated for 30 min and compared the 
data to a previous ETS1 ChIPSeq experiment in resting cells [25] (Figure 3.2a).  
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Figure 3.1 Calcium signaling to ETS1 (A) Calcium-dependant signaling 
impinges on ETS1, resulting in multiple discrete phosphorylation events in a 
serine rich region (SRR) N-terminal to the ETS domain [31]. (B) A time course of 
activation followed by protein immunoblot of Jurkat whole cell extract reveals the 
rapid modification of ETS1. Analysis with ETS1 antibody reveals an 
electrophoretic mobility shift after 2 min of stimulation and peaking at 30 min of 
phosphorylation. Analysis with an antibody specific for phospho-ETS1S251 
confirms that the observed shift is correlated with to SRR-phosphorylation.  
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Using an empirical false discovery rate of < 0.01, there were 20,439 binding 
events in the activated data set and 19,420 in the resting set. Furthermore, 68% 
of the bound regions in the activated set were included in the resting set. Of the 
nonoverlaping binding events in the activated data set, 87% are not DNase I 
hyper-sensitive [27] and, therefore, may represent false positives (Figure 3.2b). 
In spite of the high number of identified binding events, the average binomial P 
value in the activated set was 77.5 compared to 101.0 in the resting set, 
indicating that ETS1 occupancy was decreased upon activation. Qualitative 
analysis of the resting and activated ETS1 ChIPSeq data sets confirms this 
quantitative analysis. In sum, these data indicate a global reduction in ETS1 
occupancy upon activation. 
These findings were confirmed and quantified by quantitative PCR (qPCR) 
on ETS1-specific and ETS-redundant bound regions (Figure 3.3). ETS1 
occupancy was observed to dramatically decline at 3/3 ETS-redundant promoters 
and at 3/4 ETS1-specific enhancers. We calculated that the average decrease in 
ETS1 occupancy at promoters is 72+ 21% while for enhancers it is 46+23%. 
While this difference may be significant, the range of qPCR sensitivity at high 
occupancy sites (promoters) and low occupancy sites (enhancers) may not be 
comparable. These data confirm that ETS1 occupancy is disrupted upon calcium 




Figure 3.2 Signaling disrupts ETS1 occupancy genome wide (A) Log 
transformed P values of ETS1 occupancy in resting [25] and 30 min activated 
cells. Mapped sequence reads (NCBI build 36.1) are visualized using the 
integrated genome browser (http://igb.bioviz.org/). (B) With an empirical false 
discovery rate of < 0.01, 19,420 and 20,439 ETS1 binding events were 
identified in the resting and activated data sets, respectively, and 68% of the 
activated binding sites were contained within the resting set. The average 
binomial P-value associated with occupancy is 77.5  for the activated set, and 
101.0 for the resting set.  
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Disruption of ETS1 tests the time-share  
model of redundancy 
 We have proposed that redundant ETS factor occupancy could reflect 
time-sharing of an individual ETS site in a cell or the average occupancy of each 
factor across the cell population. Upon ETS1 disruption, compensation by other 
ETS factors would support a model of time-sharing on an individual site. Previous 
studies showed that GABPA is highly expressed in Jurkat T cells [14] and 
redundantly occupies housekeeping promoter sites with ETS1 [24,25], making 
the factor a good candidate for examining compensation by ETS factors. As 
described below, these two ETS factors retain a presence in Jurkat cells after 
activation. 
 We performed ChIP and qPCR to query ETS1 and GABPA occupancy in 
resting and activated cells at 30 min, representing the peak of ETS1-SRR 
phosphorylation. At 3/3 redundant promoter sites, decreased ETS1 occupancy 
after 30 min of activation was correlated with increased GABPA occupancy 
(Figure 3.4). Further, these results were not recapitulated on ETS1 specific 
binding sites (0/4). This experiment provides an example of ETS factor time 
sharing on an individual site, and validates our previous classification of specific 




The expression of genes near redundant ETS sites  
are not changed by ETS network perturbation 
ETS1 and GABPA redundantly time share high-affinity ETS sites in the 
promoters of HK genes, but do they redundantly regulate transcription? We 
hypothesize that redundancy in the ETS family establishes constitutive 
expression of HK genes [24,25]. To test whether ETS-factor target genes are 
expressed in resting Jurkat T cells, we employed an RNASeq approach, which 
enables absolute values of steady-state RNA levels to be quantified as reads per 
kilobase of exon model per million mapped reads, or RPKM, reflecting the 
number of sequence reads for a transcript normalized to its length [40].  
RNASeq was performed on poly-A selected RNA from resting Jurkat T 
cells. We mapped the expression data to annotated RefSeq mRNA transcripts 
and plotted a histogram of the RPKM associated with each transcript to 
determine a threshold for defining expression (Figure 3.5a). Using the selected 
threshold of RPKM > 5, we identified that 78% (2283/2927) of redundant ETS-
target genes were expressed, compared to only 36% (7984/21989) of the 
reference set, which contained all RefSeq genes (P < .0001). We also found that 
increased redundancy is correlated with increased expression. For example, 
genes neighboring sites occupied by ETS1, ELF1, and GABPA had an average 
RPKM value of 49.1 while genes neighboring only one ETS factor had a lower 




had an intermediate value of expression. Thus, we conclude that genes 
neighboring ETS redundant binding events are actively transcribed.   
Next, we sought to determine if the expression of ETS redundant target 
genes are affected by disrupted ETS1 occupancy. Jurkat T cells were activated 
for a 12 hr time course and RNASeq was performed on samples collected at the 
following time points: 30 min, 1 hr, 3 hr, 5 hr, 8 hr, and 12 hr. Again, the 
expression data was mapped to annotated RefSeq transcripts. We generated a 
class average expression profile of 1) transcripts proximal to ETS redundant sites 
and 2) a control gene set representing all RefSeq mRNAs (Figure 3.6a). The 
expression profile represents the fold-change in RPKM relative to the resting 
state for the gene sets. Over the 12-hr time course, the redundant ETS target 
gene set and the reference gene set exhibit the same unchanged expression 
profile. We conclude that the expression of ETS redundant target genes does not 
change upon ETS1 disruption, and we speculate that ETS1 and GABPA, and 
perhaps other ETS factors, are functionally interchangeable at these sites.  
 
ETS1 specific target genes are upregulated upon ETS  
network perturbation 
In resting Jurkat T cells, RNASeq data indicated that 66% (644/975) of 
specific ETS1-target genes were expressed above the RPKM > 5 threshold. As 
in the case of the ETS redundant gene set, this represents an enrichment over 
the 36% expression in the reference set (P < .0001). The fact that fewer ETS1 
specific targets were expressed than ETS redundant targets could be an artifact  
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of incorrect gene assignment to bound region, which was made arbitrarily based 
on proximity.  
Because we did not observe GABPA compensation at ETS1 specific sites, 
we predicted that that the expression of ETS1 specific targets would decrease 
over the time course of expression. As described above, we generated a profile 
for the change in expression the ETS1 specific target gene set over the RNASeq 
time course. Surprisingly, the class average of RNA expression of ETS1 specific 
target genes increased between 3 and 5 hr of activation (Figure 3.6a), a time 
point at which ETS1 protein is decreased. Between 3 hr and 8 hr of activation, 
81% (790/957; P < .0001) of genes in this class were upregulated more than 2-
fold, and 42% (409/790; P = 0.0018) were upregulated more than 3-fold. The 
RNASeq findings were confirmed for 10/10 genes of genes by RT-qPCR (subset 
shown Figure 3.6b). 
There are many possible explanations for why ETS1 specific target genes 
are upregulated at time points depleted for ETS1 protein. Here, we explore only 
one of several possible scenarios: that an ETS factor other than ETS1 or GABPA 
mediates this transcriptional upregulation.  
 
ETS2 may control of a subset of nonredundant genes 
The genome wide binding profiles of only a handful of ETS factors have 
been characterized [21,25,41,42]. We determined the profile of expression of all 
ets genes across the RNASeq time course to identify candidate factors for 
mediating the observed upregulation. Comparison of the resting state RNASeq 
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data to previously determined mRNA copy number for each ets gene [14] found 
good correlation between the two methods (Figure 3.7), with 13 genes expressed 
at levels above background. While the expression of the majority of the 28 
human ets genes did not change over the 12-hr time course, we did observe 
changes in several family members. Upregulated genes included etv5 (14-fold at 
12 hr), elf1 ( 2-fold at 8 hrs), and ets2 (2-fold at 5 hr), while down-regulated 
genes included ets1 (2-fold at 5 hr) and etv6 (3.2-fold 5 hr) (Figure 3.8a). 
Western blot analysis tested protein levels of ETS1, ETS2, and ELF1 and 
indicated that protein levels were more dramatically affected than mRNA levels 
(Figure 3.8b). Western blots for ETV5 and ETV6 showed no change, thus, did not 
reflect the changed mRNA expression (data not shown), possibly due to post-
translational regulation of these factors.  
Increased ETS2 at 5 hr postactivation corresponds to increased 
expression of ETS1 specific gene targets at this time point. Thus we speculate 
that ETS2 might be a replacement for ETS1 at these sites. It was previously 
reported that there is a reciprocal relationship between ETS1 and ETS2 
expression upon T cell activation [39,43]. Further experiments, which require 
development of more robust ETS2 antibodies, will explore this possibility.  
 
Discussion 
The work presented in this chapter supports a model of ETS factor 
redundancy wherein ETS factors co-expressed in a single cell share occupancy 




Figure 3.8 Perturbation of the ETS network (A) The expression of several ETS 
genes was affected by cell signaling. Upregulated genes included etv5 (14-fold at 
12 hr), elf1 ( 2-fold at 8 hrs), and ets2 (2-fold at 5 hr), and down-regulated genes 
included ets1 (2-fold at 5 hr) and etv6 (3.2-fold 5 hr). (B) Immunoblot analysis on 
whole cell extracts show that the increase in ETS1, ETS2, and ELF1 protein was 
more dramatic than the increase in mRNA. Immunoblot analysis for ETV5 and 
ETV6 showed no change in protein (data not shown). 
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network and profiling the expression of ETS target genes, distinct behavioral 
differences were identified for redundant ETS targets and specific ETS1 targets, 
further establishing that different recruitment motifs mediate distinct 
transcriptional functions of ETS1. Unexpectedly, ETS1 specific target genes were 
transcriptionally upregulated upon disruption of ETS1 binding, setting the stage 
for future experiments examining whether these sites are truly ETS1 specific. 
These findings add new complexity to the working model of ETS factor specificity 
and redundancy, and indicate that these delineations may not apply to all 
contexts. We put forth a model of ETS factor function which represents 
redundancy and specificity as a continuum rather than a dichotomy, particularly 
for closely-related family members (Figure 3.9).  
 
The upregulation of ETS1-specific sites 
The unexpected upregulation of ETS1 specific target genes could be 
mediated by a number of different mechanisms. While it is certainly possible that 
a non-ETS transcription factor mediates the observed upregulation, it is not 
unreasonable to predict regulation by a previously unconsidered ETS factor as 
the affected class of genes is correlated with an ETS binding motif, albeit a low-
affinity motif. 
Above, we have presented a straight forward model wherein the 
upregulation of ETS2 compensates for ETS1 disruption. Our lab previously found 
that ETS2 is minimally phosphorylated by CaMKII and that calcium signaling 
does not attenuate ETS2 DNA binding affinity (D. C. unpublished data). Upon T  
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 cell activation, the concentration of cyctoplasmic Ca2+ oscillates [44], which 
would disrupt transcription driven by ETS1 but presumably not ETS2. This 
difference between the two factors could facilitate ETS2 occupancy at these sites 
in the presence of calcium-dependant signaling, but it is unresolved whether the 
transcriptional properties of ETS2 are equivalent with those of ETS1.  
Beyond a simple interchange of ETS2 for ETS1, RAS-MAPK signaling to 
one or both factors may play a role in the upregulation of this gene set. This 
chapter focused on calcium signaling to the ETS network, but T cell receptor 
engagement also activates the RAS-MAPK pathway [45]. The RAS-activated 
kinase ERK1/2 phosphorylates ETS1 and ETS2 in a conserved, unstructured 
region N-terminal to the PNT-domain [46]. This phosphorylation event increases 
the factorsʼ transcriptional activity via an enhanced interaction between ETS1/2-
PNT and the transcriptional co-activator CBP/p300, [47]. Our study found that 
ERK1/2 is no longer activated at the 5 hr time point (data not shown), but RAS 
signaling to ETS2, or residually bound ETS1, may still play a role in the observed 
upregulation of genes. We speculate that stably bound ETS1 may be modified by 
ERK-phosphorylation. Unfortunately, attempts to detect this phosphorylated 
ETS1 species at target sites with ChIP experiments and a phosphospecific 
antibody have not been successful.  
 
Redundancy within the ETS family  
Shifting the equilibrium of ETS1 occupancy affected the occupancy of 
other ETS factors, providing evidence that ETS factors share time on an 
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individual binding site. While expression data indicate that ETS factors perform a 
redundant function at HK promoters, the function is still unknown. In vitro 
functional studies have shown that ETS1 recruits the co-activator CBP/p300 to 
activate transcription [48]. A number of other ETS factors interact with CBP/p300, 
including ETS2 [49], PU.1 [50], GABPA [51], and ELK1 [52], and it has been 
suggested that recruitment of CBP/p300 to promote transcription could be the 
redundant function of ETS factors. Countering this possibility, the in vivo survey 
of CBP occupancy presented in Chapter 2 identified a CBP profile distinct from 
ETS1 and GABPA at HK promoters [25]. It is possible that ETS factors recruit 
CBP to HK promoters and subsequently ʻhand-offʼ CBP to another molecule, 
such as acetylated histone via the CBP bromo-domain [53,54], but here we 
consider other mechanisms of redundancy. 
Outside of the ETS domain, there is considerable diversity across the 
family. Perhaps the redundant function of the ETS family simply requires site 
occupancy. The strong occupancy of ETS factors at sites near a TSS could act 
as a place holder, maintaining or establishing open chromatin to facilitate 
transcriptional activation by other factors. Consistent with this possibility, we 
found that redundant ETS binding events occur in a nucleosome free region 
(NFR), about 25 bp upstream of the TSS [25]. Redundant preference for high 
affinity sites ensures a site is always occupied, and could serve to establish a 
transcriptionally permissive environment at genes requiring constitutive 
expression. 
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The promoters of HK genes are CpG rich and largely hypo-methylated 
(reviewed in [55]), which is essential for maintaining active chromatin and 
facilitating constitutive expression. The preferred ETS site contains a CpG 
dinucleotide in the core recognition site, and several ETS factors have been 
shown to be sensitive to DNA methylation [56,57]. Further, comparisons of 
methylation patterns and ETS factor occupancy reveal a correlation between the 
ETS site and hypo-methylation (data not shown). Thus, ETS factors could play a 
role in maintaining hypo-methylation at housekeeping promoters, contributing to 
the preservation of a transcriptionally permissive environment. This mechanism 
of protection by a transcription factor has been shown for the MLL, which protects 
a CpG-containing binding site in the Hoxa9 promoter from methylation and 
thereby promotes transcription [58].  
 
Binding site sequence dictates behavior  
We previously reported that unique recruitment motifs at ETS1 targets are 
correlated with distinct co-activator recruitment profiles, histone landscape, and 
genomic location [25]. Here, we have expanded on that finding to show that 
binding site sequence dictates distinct behaviors upon ETS network perturbation. 
Historically, transcription factor binding sites were viewed as platforms to recruit 
transcriptional machinery, not as tunable elements of transcriptional behavior. It 
is becoming clear, however, that most transcription factors bind to more than one 
distinct binding site, which may be associated with unique transcriptional 
mechanisms. Studies on the transcription factor glucocorticoid receptor (GR) 
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have shown that DNA can act as an allosteric-ligand and that site sequence can 
influence distinct conformations, and thereby transcriptional functions, of GR [59]. 
In vitro structural studies on PU.1 have shown that the DNA binding domain 
makes unique base-contacts with low-affinity and high-affinity sites [60], resulting 
in unique conformational complexes directed by different binding sites.  
Considering the use of diverse DNA binding sites on a larger scale, the 
binding preferences of 104 transcription factors were assessed using protein-
binding microarrays, revealing that approximately half of the factors considered 
bound to two or more distinct DNA motifs [61]. Our analysis of the behavior of 
unique ETS1 binding motifs has considered only two sites, but further genomic 
exploration of the ETS family will no doubt identify additional motifs and expand 
our current understanding of ETS factor function.  
 
The continuum of ETS factor specificity  
 We report that previously identified ʻETS1 specificʼ binding events are 
associated with up regulated genes upon ETS1 disruption, leading us to 
hypothesize that ETS2, the ETS factor most related to ETS1, may be involved. 
The function of ETS1 and ETS2 is not entirely redundant, however, and mouse 
models predict a subset of unique functions for each factor [11,62,63,64]. In vitro, 
ETS2 was found to bind the consensus ETS site with 10-fold lower affinity than 
ETS1 (unpublished data), and the factors respond differentially to calcium 
signaling. Thus, further consideration of ETS1 and ETS2 can serve to address 
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the ways in which closely-related factors establish unique functions within the 
context of the family. 
The work presented in this chapter highlights the importance of studying 
the ETS family as a network rather than as individual factors. Delineations of 
ʻspecificʼ and ʻredundantʼ are no doubt too stringent for what is really a complex 
continuum of functionality within the family.   
 
Materials and methods 
T cell culturing and activation 
Jurkat T cells (E6 line) were cultured in RPMI media supplemented with 
10% FBS, 1X Pen/Strep, 10mM sodium pyruvate, and 10mM HEPEs buffer, and 
incubated at 37°C with 5% CO2. T cell activation was recapitulated by treating 
confluent cultures with 2uM ionomycin (I9657Sigma) and 20uM PMA (Phorbol 
12-myristate-13-acetate, P8139 Sigma) for the indicated incubation times.  
 
Immunoblot analysis  
Immunoblot analysis was performed by harvesting 10x106 Jurkat cells, 
centrifuging at 500 x g for 5 min at 4°C, and resuspending whole cell pellets in 
SDS loading buffer (1uM DTT) to a concentration of 40,000 cells/uL. 
Resuspended pellets were sonicated and incubated at 95°C for 5 min. The 
extract of 600,000 cells was then loaded on a 10% polyacrylamide SDS gel and 
run at 200 V for 45 min at RT. Samples were transferred to a nitrocellulose 
membrane at 250 mA for 2 hr at 4°C. Membranes were blocked with 5% dry 
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milk:1X PBS (pH 7.4) for 30 min at RT. Primary antibody incubation was 
performed overnight at 4°C, and washed 4x for 5 min each (1X PBS, pH 7.4). 
Secondary antibody conjugations were performed for 1.5 hr at RT. Immunoblots 
were developed using SuperSignal® West Femto Maximum Sensitivity Substrate 
(Pierce, 34094). Antibodies used: ETS1 C20 (Santa Cruz; sc-350), ETS1T251P 
(Biosource; 44-1109G), ETS2 (Santa Cruz; sc-22803), ELF1 (Santa Cruz; sc-
631), GABPa (Santa Cruz; sc-22810), and Tubulin (Santa Cruz; sc-5546).  
 
ChIP experiments (qPCR) 
ChIP experiments were performed as previously published [24]. In short, 
50 x106 cells were cross linked with 1% formaldehyde at RT for 15 min. The 
crosslinking was quenched with 100mM Glycine for 5 min, then washed with 1X 
PBS (pH 7.4). The cells were then lysed, nuclei washed, and resuspended in a 
nuclei lysis buffer. The crosslinked chromatin was sonicated by a Misonix 
Ultrasonic processor using 10X 20 sec pulses at a Power Level of ʻ4ʼ. The 
sonicate was cleared for 10 min at >16,000 RPM, and the lysate of 10 x106 cells 
was used for each IP. Sonicate was added to 100 uL Dyna-beads (Invitrogen; 
Dynabeads® M-280) conjugated to ~5 ug antibody, and rotated at 4°C for 4 hr. 
IPs were  washed 4X with 250mM salt and eluted in 10mM Tris (pH 7.9). The 
eluate was treated with RNaseA (Invitrogen; 12091-039) for 20 min at 37°C, and 
crosslinks were reversed overnight with ProteinaseK treatment (Invitrogen; 
AM2546). Samples were purified using a Qiaquick column (Qiagen; 28104), and 
the eluate was assayed for enrichment by qPCR using target specific primers 
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(Table 3.1) and the Roche480 system (Roche Applied Science; 04707516001) as 
previously described [24,25]. 
  
ChIPSeq analysis  
ChIP DNA was size selected (100-500 bp fragments) and was single end 
sequenced with 36 cycles on an Illumina HiSeq GAII using standard protocols for 
preparing and sequencing libraries. ChIPSeq data was processed and analyzed 
as previously described [25] using the USeq software package 
(http://useq.sourceforge.net) [65]. Human genome sequence was obtained from 
the UCSC Genome Browser (March 2006, NCBI Build 36.1, HG18), and data 
was visualized with the Integrated Genome Browser (IGB, http://igb.bioviz.org/).   
 
Expression profiling  
RNA was isolated from 1X106 Jurkat cells using the Qiagen RNeasy 
Extraction kit (Qiagen; 74104) coupled with the QiaShredder Column (Qiagen; 
79654) and an on-column DNase digestion (Qiagen; 79254). The isolated RNA 
was either assayed by RT-qPCR or by RNASeq. For RT-qPCR, RNA was 
reverse transcribed using SuperScript® III First-Strand Synthesis System and 
standard protocol (Invitrogen; 18080-051). The samples were RNaseH 
(Invitrogen; 18021-071) treated for 30 min at 37°C and cleaned using the Qiagen 
PCR cleanup kit. qPCR was performed using site specific primers (Table 3.2) 




For RNASeq, the extracted RNA was polyT selected and sequenced using 
the Illumina HiSeq GAII after a standard library preparation protocol. Sequences 
were aligned using the TopHat aligner (http://tophat.cbcb.umd.edu/) with a splice 
junction radius of 45 bp, and annotation was obtained from UCSC (March 2006, 
NCBI Build 36.1, HG18). Absolute expression levels were identified using the 
USeq bioinformatics package [65]. 
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SUMMARY, DISCUSSION, AND FUTURE DIRECTIONS 
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A genomic approach to the ETS network 
At all levels of biological complexity – from a single cell to high order 
organisms – transcriptional regulation dictates the complex and coordinated gene 
expression programs required for proper growth, development, and function. 
Much of this diversity is achieved through the use of distinct transcription factors 
(TFs). Most TFs exist in the context of highly related families that exhibit 
functional specificity in spite of a high degree of homology. Understanding how 
related factors establish unique functions is central to the understanding of 
transcriptional regulation and cell biology as a whole.  
 
Summary of genome-wide ETS studies 
 Genome wide studies have begun to reveal the global distribution of ETS 
factor binding events, and these studies have shown that ETS factors are 
recruited to DNA by both redundant and specific regulatory elements. With a 
focus on ETS1, the work presented in this dissertation refines the model of ETS 
family function by identifying architectural, genomic, biological, and behavioral 
differences between different types of ETS1 occupied regulatory elements.  
In Chapter 2, we established that ETS-redundant and ETS1-specific 
regulatory elements are associated with distinct chromatin landscapes, DNA 
recruitment motifs, and ontological gene sets. Using a genome wide approach, 
we expanded our understanding of specific ETS1-sites to include a large number 
previously unidentified distal transcriptional enhancers. These ETS1-specific 
binding events were found to be mediated by a degenerate ETS binding motif, 
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and in many cases the nearest gene was associated with T cell biology. 
Overlaying histone mark profiles on ETS-factor occupancy data, we found that 
ETS-redundant and ETS1-specific regulatory elements are correlated with marks 
of active promoters and transcriptional enhancers, respectively. We also found a 
striking co-localization of ETS1 and the transcriptional co-activator CBP at 
enhancers, but not at promoters, suggesting that ETS1 may behave differently at 
these two recruitment sequences.   
In Chapter 3, we disrupted ETS1 binding in vivo to reveal distinct 
behaviors for ETS-redundant and ETS1-specific target genes, illustrating the 
distinct biological functions mediated by ETS1. At redundant promoters, 
disruption of ETS1 occupancy revealed the first example of dynamic time sharing 
by ETS1 and GABPA, establishing the basis of redundancy within the ETS 
family. Further, this time sharing had no effect on the expression of nearby 
genes, suggesting functional redundancy for ETS factors at these sites. Time 
sharing was not observed at previously identified ETS1-specific sites, indicating 
that specificity is not an artifact of competition. Unexpectedly, the average 
transcription of genes near ETS1-specific binding events was increased upon 
ETS1 disruption, and we hypothesize that this could be due to the concurrent 
increase in ETS2 protein. These results have important implications for 
understanding how ETS1 functionally mediates different transcriptional programs, 
and suggests a model of ETS family function wherein specificity is a continuum 




Refining the model of ETS family function 
The work presented in this dissertation uses data sets generated by the 
massively parallel DNA sequencing techniques ChIPSeq and RNASeq to refine 
the model of ETS family function in vivo. At the commencement of this work, 
ChIP-on-chip using promoter microarrays had revealed a subset of redundant 
and specific ETS factor binding events in Jurkat T cells [1]. While these studies 
provided a conceptual framework for understanding and describing ETS factor 
binding in the cell, the use of probe-based techniques like microarray limited both 
the resolution and comprehensiveness of the working model. As presented in 
Chapter 2, the use of ChIPSeq – a massively parallel DNA sequencing technique 
which does not rely on the use of predefined probes – allowed us to interrogates 
factor occupancy genome-wide rather than at a subset of preselected genomic 
loci. We expanded our understanding of the ETS family model to include a large 
number of distal transcriptional enhancers, including 12,283 ETS1-bound 
enhancers (>500 bp from TSS) [2] which would not have been identified by 
promoter microarrays.  
Transcription factor binding does not presage transcription factor function, 
however, and functional validation of ChIPSeq data is required. Correlating in 
vivo factor occupancy with endogenous gene expression provides a biologically 
relevant way to confirm functionality and has identified novel functional 
mechanisms for transcription factors like estrogen receptor (ER) and p53 [3,4]. 
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While it was clear that determining the expression profiles of putative ETS targets 
would add detail to the model of ETS factor function, the probe-based expression 
microarrays available at the commencement of this work presented a major 
obstacle for these studies. Inherent differences in microarray probe efficiency 
require the comparison of experimental data sets to null or control sets, which 
limits the utility of microarry to asses the expression of widely expressed genes 
like housekeeping genes. Other methods of establishing transcription, such as 
correlation of HK gene promoters with DNaseI hypersensitivity, H3K4me3, and 
PolII occupancy, had suggested that genes near redundant ETS sites were 
actively expressed [5,6,7,8], but direct evidence of active transcription was still 
lacking. In Chapter 3, we presented evidence that both redundant and specific 
ETS factor binding is correlated with positive transcription of neighboring genes. 
Using RNASeq – a quantitative, rather than qualitative, method of examining 
global gene expression – we established that 78% of genes near redundant ETS 
binding events and 66% of genes near ETS1 specific binding events are actively 
transcribed. This finding supports our prediction that ETS factors function as 
transcriptional activators at these sites and refines the model of the ETS family.  
Taken together, genome wide sequencing techniques have added new 
features to the portrait of ETS family function. The overlay of new data sets for 
additional TFs, DNA methylation, and nucleosome positioning. Below, we discuss 
several of the outstanding questions related to the working model of the ETS 
family, including the functional mechanisms of redundancy and specificity, and 
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the implications of our finding in Chapter 3 that ETS1 and ETS2 may function on 
a continuum of specificity.  
 
The redundant role of the ETS family 
The degree of redundancy between ETS1, GABPA, and ELF1 was 
surprising, but previous to our finding there was evidence that ETS factors play a 
role in HK gene expression. HK gene promoters are CpG rich and an 8-mer high 
affinity ETS site, 5ʼ-VCCGGAARY-3ʼ, is over represented in HK promoters [9,10]. 
Further, CpG rich promoters containing the 5ʼ-VCCGGAARY-3ʼ site frequently 
have high PolII occupancy across multiple cell types [7,8], suggesting constitutive 
expression of nearby genes. These observations independently validate our 
finding that high affinity ETS factor binding in vivo is correlated with actively 
transcribed HK genes.  
In addition to establishing the transcription of genes near redundant 
binding sites, we have shown that expression levels are unchanged as ETS1 
occupancy is disrupted and GABPA occupancy is increased. This finding 
suggests functional redundancy at ETS consensus sites, but it is unclear if the 
redundancy of ETS factors is entirely universal across the family. To date, 
genome wide studies of ETS factors have surveyed the occupancy of ETS 
factors with relatively divergent ETS domains, and have consistently found 
striking redundancy at HK promoters [2,11,12,13]. These findings suggest a 
universally redundant function of ETS factors, but systemic assessment of the 
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family must be performed to directly establish redundancy for all ETS family 
members.  
Perhaps more significantly, however, the mechanism of redundant 
function is not understood, and there are many possible roles for ETS factors at 
HK promoters. Co-activator recruitment is an attractive possibility for the 
redundant function of ETS factors as many family members, including ETS1 [14], 
ETS2 [15], PU.1 [16], GABPA [17], and ELK1 [18], interact with the 
transcriptional co-activator CBP/p300. However, many of these ETS factors 
interact with CBP/p300 via the PNT interaction domain, and it is unlikely that all 
ETS factors can form interactions with CBP/p300. Further, fine mapping of our 
ChIPSeq data found that ETS1 and GABPA do not co-localize with CBP at HK 
promoters [2]. It is certainly possible that ETS factors recruit CBP to HK 
promoters but do not remain physically associated after recruitment, but other 
mechanisms of redundancy should be considered.  
The most conserved structural domain across the ETS family is the ETS 
domain, and it is possible that redundancy is mediated through this domain. This 
could be established through a conserved protein partnership mediated by the 
ETS domain, and while pull-down experiments using the ETS domains of various 
ETS factors have yet to observe evidence of a common interacting protein, it 
remains an interesting possibility. 
It is also possible that the ETS domain could mediate redundant function 
simply through the act of physically occupying a DNA binding site and protecting 
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it from methylation. The promoters of HK genes are CpG rich and largely hypo-
methylated (reviewed in [19]), which is essential for maintaining active chromatin 
and facilitating constitutive expression. Several ETS factors have been shown to 
be sensitive to CpG methylation [20,21], and comparisons of methylation patterns 
and ETS factor occupancy reveal a correlation between the consensus ETS site 
and hypo-methylation (data not shown). Thus, ETS factors could play a role in 
maintaining hypo-methylation at housekeeping promoters and establishing a 
transcriptionally permissive environment. This mechanism of protection by a 
transcription factor has been shown for MLL, which protects a CpG-containing 
binding site in the Hoxa9 promoter from methylation and thereby promotes 
transcription [22].  
Yet another possible mechanism of ETS factor function at redundant 
promoters could be through the positioning of promoter nucleosomes. If ETS 
factors can compete with nucleosome occupancy, they may play a role in 
establishing the nucleosome free region (NFR) at HK promoters. Bioinformatic 
analysis has revealed that redundant ETS binding events occur in the NFR, 
about 25 bp upstream of the TSS [2]. By helping to establish open chromatin at 
the TSS, ETS factors may promote binding of other TFs to their binding sites 
[23]. Future experiments will address the possibility of ETS factor competition 





Specific functions of the ETS family 
The potential for competition between ETS factors and nucleosomes may 
also be relevant to ETS1 function at transcriptional enhancers. Bioinformatic 
analysis reveals that many TF binding sites occur between nucleosomes [24], 
and in Chapter 2 we reported that well positioned nucleosomes flank ETS1 
binding at enhancer regions. We hypothesize that the role of ETS1 at these sites 
may be to ʻset-upʼ the transcriptional enhancer for activation, positioning 
nucleosomes such that factors involved in T cell activation can immediately 
access binding sites upon signaling. Indeed, it is thought that inducible 
recruitment of NF-kB is guided by the pre-set chromatin state [25], and ETS1 
could play a role in determining the resting state nucleosome framework. It is 
also possible that the clearing of ETS1 from transcriptional enhancers upon 
activation may be a key step in the regulation of these gene targets. 
Alternatively, ETS1 could set up T cell specific enhancers by recruiting 
additional factors to the site, establishing a transcriptionally permissive 
environment. In Chapter 2, fine mapping of enhancer sites revealed co-
localization of ETS1 with CBP and the TF RUNX1, suggesting the establishment 
of an ʻenhancesomeʼ complex at these sites. ETS1 or the associated factors 
could play a role in the recruitment of histone modifying enzymes to establish the 
observed pattern of H3K4me1/3 at transcriptional enhancers [6,26].  
The observation that the majority of ETS1 specific occupancy occurs at 
distal enhancers was significant to the understanding of ETS family function, and 
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is consistent with meta-analysis of genomic data sets indicating that distal 
regulatory elements mediate cell type specificity [27]. Interestingly, the most over 
represented binding site at ETS1 specific binding events is 5ʼ-CAGGAA/T-3ʼ, 
which unlike the ETS redundant site, does not contain a CpG dinucleotide [1]. It 
has been suggested that in general, transcription factor binding sites which 
contain a CpG are constitutively expressed while binding sites which do not 
contain a CpG are involved in regulated, and often inducible, gene expression 
[10]. This suggestion is consistent with our findings for the ETS family, and 
consideration of non-CpG containing ETS sites may contribute to the 
identification of other ETS factor specific DNA recruitment motifs.  
 
Specificity and redundancy within ETS subgroups- the ETS  
family continuum 
 In Chapter 3, we reported that previously identified ʻETS1 specificʼ binding 
events are associated with upregulated genes upon ETS1 disruption, leading us 
to hypothesize that ETS2, the ETS factor most related to ETS1, may play a role. 
ETS1 and ETS2 are not entirely interchangeable, however, and mouse models 
predict a subset of unique functions for each factor [28,29,30,31]. In vitro, ETS2 
was found to bind the ETS consensus site with 10-fold lower affinity than ETS1, 
and the factors respond differentially to calcium signaling (D.O. Cowley, PhD 
thesis). Thus, further consideration of ETS1 and ETS2 can serve as a model-
within-a-model, addressing how closely-related factors establish redundant and 
specific functions within the greater context of the family.  
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 There are other examples of closely-related ETS factors being implicated 
in redundant but cell-type specific roles. In Ewingʼs sarcoma, the closely related 
ETS factors ERG, FLI, and FEV have been implicated in oncogenesis, but so has 
the more distantly related ETV1 [32,33,34,35]. Within the PEA3 subfamily, ETV1, 
ETV4, and ETV5 have been implicated in a redundant oncogenic function in 
prostate cells [36], but again a more distantly related ETS factor, ERG, has been 
implicated in this role. These oncogenic ETS represent two disparate clades in 
the family.  These findings suggest that while ETS factors function on a 
continuum of specificity, the distribution of the continuum may not be solely 
influenced by evolutionary conservation.  
These examples highlight the importance of studying the ETS family as a 
network rather than as individual factors, and the work presented in this thesis 
has proven the utility of studying the ETS family in a dynamic system. 
Delineations of ʻspecificʼ and ʻredundantʼ are no doubt too stringent for what is 
really a complex continuum of functionality within the family, and future work in 
the T cell and other systems will no doubt reveal additional subtleties to the 




 The work presented in this dissertation frames a number of interesting 
future directions. Immediate future work will address the possible interchange of 
ETS1 and ETS2 at a subset of genomic loci. The time course expression data 
could also be examined for further expression patterns correlated with 
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established or putative ETS binding events. Additionally, addressing the interplay 
between ETS factor binding and nucleosome occupancy may provide 
mechanistic insight into the role of ETS factors in genome organization, both at 
promoters and enhancers.  
 
Determine the in vitro binding affinity of ETS2  
at enhancer sites 
The hypothesis presented at the end of Chapter 3 suggests that ETS1 and 
ETS2 may bind redundantly to the degenerate ETS site found at many enhancer 
regions. The viability of this hypothesis can be tested by determining the in vitro 
DNA binding affinity of ETS2 for the enhancer site. We have found that ETS2 
binds to the consensus ETS site with 10-fold lower affinity than ETS1 (D.O. 
Cowley, PhD thesis), and lower affinity for an already weak site may prevent 
significant ETS2 binding. Thus, establishing the feasibility of this hypothesis will 
require an examination of ETS2 binding affinity for the enhancer ETS site.  
 
Determine the in vivo genomic occupancy of ETS2  
at enhancer sites 
Another approach to testing the hypothesis that ETS2 compensates for 
ETS1 at a subset of low-affinity ETS sites is to determine in vivo occupancy  by  
ChIP qPCR. Alternatively, a genomic approach could be taken to this experiment 
and ETS2 ChIPSeq could be performed on activated cells. The advantage of the 
latter approach is the potential to discover ETS2 binding events unique from the 
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previously identified ETS1 binding events. A caveat to this experiment is that 
commercially available ETS2 antibodies have not been successful for ChIP.  
 
Identify inducible genes near non-ETS1 occupied  
ETS binding sites 
 The work presented in this dissertation has focused largely on the specific 
functions of ETS1 in the dynamic T cell system. In Chapter 3, we presented data 
that the expression of ETS factors other than ETS1 and ETS2 are affected upon 
system perturbation. Notably, ETV5 is upregulated ~20-fold while ETV6, which is 
thought to be a transcriptional repressor, is downregulated. By identifying a set of 
changed genes with nearby ETS binding sites – though not necessarily ETS1 
occupancy – new levels of dynamic regulation in the ETS family could be 
uncovered. 
 
Perform in vitro competition assays between ETS  
factors and nucleosomes 
We have suggested that the mechanism of redundancy for the ETS family 
is to permanently occupy high affinity sites and effectively occlude nucleosomes. 
We could test this hypothesis by constructing an in vitro chromatin template with 
a nucleosome-buried high-affinity ETS site. This chromatinized template could 
then be used in competition experiments with a minimal-ETS domain, revealing 
kinetic data for competition between ETS factors and nucleosomes. It poses a 
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caveat, however, in that chromatin templates in vitro may not represent the 
biological placement of chromatin in vivo.  
 
Bioinformatically assess the model of ETS  
factor- nucleosome competition  
Evidence for this mechanism could also be determined bioformatically. If 
ETS factors bind high-affinity sites to position nucleosomes, we predict that high-
affinity ETS sites should occur either between nucleosomes, where an ETS factor 
has already competed away nearby nucleosomes, or buried within a 
nucleosome, where the site is inaccessible. Binding sites located at nucleosome-
borders would be partially accessible due to nucleosome dynamics, or chromatin 
breathing, and binding of ETS factors would drive these sites to become inter-
nucleosomal. Thus, if we observe high-affinity ETS sites at nucleosome-borders, 
the ʻcompetitionʼ mechanism of redundancy is less likely. 
 
Final summary 
 In summary, the studies described within this dissertation identified distinct 
characteristics for redundant and specific ETS1 regulatory elements. Using 
massively parallel DNA sequencing techniques, this work adds new levels of 
detail to the model of ETS family function. In Chapter 2, this thesis presented the 
first genome wide occupancy profile of ETS1 and CBP, and comparison of this 
data to other genome wide data sets highlighted the distinct characteristics of 
redundant promoters and specific enhancers. The work presented in Chapter 3 of 
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this thesis revealed the first example of dynamic sharing of ETS factors in vivo, 
and suggested a molecular basis for the widely observed redundancy across the 
family. Expression data identified distinct behaviors for genes near different 
binding sites, further indicating that biological function is correlated with DNA 
binding site sequence. These results serve as a framework for future studies 
investigating the specificity and redundancy of ETS factors, particularly closely-
related ETS factors, in an in vivo context.  
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